

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A crystalline tolterodine tartrate form I, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 11.9, 13.6, 14.2, 15.9, 16.9, 18.4, 18.8, 20.4, 22.0, 23.9, 25.4, 26.3 and 29.8 degrees.
2. (Previously Presented): The crystalline tolterodine tartrate form I as defined in claim 1, further characterized by an x-ray powder diffraction spectrum as in FIG. 1.
3. (Previously Presented): The process for preparation of tolterodine tartrate form I as defined in claim 1, which comprises the steps of: a) dissolving tolterodine free base in a suitable solvent; b) adding tartaric acid; and c) isolating tolterodine tartrate form I; wherein the suitable solvent is selected from the group consisting of ethanol, methylene dichloride, chloroform, acetone, acetonitrile and 1, 4-dioxane.
4. (Previously Presented): The process according to claim 3, wherein the suitable solvent is ethanol.
5. (Previously Presented): The process according to claim 3, wherein the suitable solvent is acetone.
6. (Original): A crystalline tolterodine tartrate form II, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 8.7, 9.0, 9.6, 10.1, 10.4, 11.9, 14.0, 15.7, 16.9, 17.6, 17.9, 18.4, 18.7, 20.0, 20.5, 22.1, 24.5, 29.1 and 35.9 degrees.

7. (Previously Presented): The crystalline tolterodine tartrate form II as defined in claim 6, further characterized by an x-ray powder diffraction spectrum as in FIG. 2.

8. (Previously Presented): The process for preparation of tolterodine tartrate form II as defined in claim 6, which comprises the steps of: a) dissolving tolterodine free base in ethyl acetate; b) adding tartaric acid; and c) isolating tolterodine tartrate form II.

9. (Original): A crystalline tolterodine tartrate form III, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 9.1, 9.7, 10.6, 11.7, 11.9, 12.7, 14.3, 15.7, 17.9, 18.5, 18.8, 19.1, 20.1, 20.4, 22.1, 22.5, 25.1, 32.8 and 35.5 degrees.

10. (Previously Presented): The crystalline tolterodine tartrate form III as defined in claim 9, further characterized by an x-ray powder diffraction spectrum as in FIG. 3.

11. (Previously Presented): The process for preparation of tolterodine tartrate form III as defined in claim 9, which comprises the steps of: a) dissolving tolterodine free base in methyl tert-butyl ether; b) adding tartaric acid; and c) isolating tolterodine tartrate form III.

12. (Original): A crystalline tolterodine tartrate form IV, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 7.8, 9.8, 15.2, 17.2, 17.7, 18.4, 18.9, 20.3 and 25.9 degrees.

13. (Previously Presented): The crystalline tolterodine tartrate form IV as defined in claim 12, further characterized by an x-ray powder diffraction spectrum as in FIG. 4.

14. (Previously Presented): The process for preparation of tolterodine tartrate form IV as defined in claim 12, which comprises the steps of: a) mixing tolterodine tartrate, an alcohol and water; and b) removing the solvents from the solution formed in step (a) by freeze drying; wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol and n-

butanol.

15. (Previously Presented): The process according to claim 14, wherein the suitable alcohol is methanol.

16. (Previously Presented): The process according to claim 14, wherein the suitable alcohol is ethanol.

17. (Original): Amorphous tolterodine tartrate characterized by an x-ray powder diffraction spectrum as in FIG. 5.

18. (Previously Presented): The process for preparation of amorphous tolterodine tartrate as defined in claim 17, which comprises the steps of: a) mixing tolterodine tartrate, an alcohol and water; and b) removing the solvents from the solution formed in step (a) by vacuum drying or by spray drying; wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol and n-butanol.

19. (Previously Presented): The process according to claim 18, wherein the suitable alcohol is methanol.

20. (Previously Presented): The process according to claim 18, wherein the suitable alcohol is ethanol.

21. (Previously Presented): The process according to claim 18, wherein the solvents are removed by vacuum drying.

22. (Previously Presented): The process according to claim 18, wherein the solvents are removed by spray drying.

23. (Original): A pharmaceutical composition comprising a polymorphic form of tolterodine tartrate and a pharmaceutically acceptable carrier or diluent.

24. (Currently Amended): The pharmaceutical composition as defined in claim 24 23, wherein the polymorphic form is tolterodine tartrate form I of claim 1.

25. (Currently Amended): The pharmaceutical composition as defined in claim 24 23, wherein the polymorphic form is tolterodine tartrate form II of claim 6.

26. (Currently Amended): The pharmaceutical composition as defined in claim 24 23, wherein the polymorphic form is tolterodine tartrate form III of claim 9.

27. (Currently Amended): The pharmaceutical composition as defined in claim 24 23, wherein the polymorphic form is tolterodine tartrate form IV of claim 12.

28. (Currently Amended): The pharmaceutical composition as defined in claim 24 23, wherein the polymorphic form is amorphous tolterodine tartrate of claim 17.